GleamWall
中文EN

CNTX Context Therapeutics Inc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1842952 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY-66.0%
TTM EPS YoY-91.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-84.3%
ROA-75.8%
ROIC (approx.)—
Asset turnover—

Leverage & solvency

Liabilities / assets15.1%
Debt / equity0.00x
Current ratio6.59x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.77x
Accruals ratio-17.1%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue————————
R&D expense$5.72M$12.53M$7.02M$11.84M$8.72M$7.83M$3.46M$2.52M
SG&A expense$2.24M$2.44M$2.33M$1.96M$1.89M$1.93M$2.07M$1.79M
Operating income-$7.96M-$14.97M-$9.34M-$13.80M-$10.61M-$9.76M-$5.53M-$4.31M
Net income-$7.62M-$14.56M-$8.68M-$13.03M-$9.69M-$8.83M-$4.58M-$3.34M
EBITDA-$7.95M-$14.96M-$9.34M-$13.80M-$10.61M-$9.75M-$5.53M-$4.31M
EPS (basic)-0.08-0.15-0.09—-0.10-0.09-0.05—
EPS (diluted)-0.08-0.15-0.09—-0.10-0.09-0.05—
Weighted avg. shares (diluted)95.18M95.18M95.18M—95.19M95.19M95.19M—
Balance sheet
Cash & equivalents$34.41M$42.99M$54.53M$66.00M$76.94M$83.52M$89.35M$94.43M
Current assets$36.27M$45.82M$58.52M$68.35M$79.06M$86.95M$92.73M$97.90M
PP&E, net$66,599$74,068$62,227$29,656$33,721$37,787$41,852$11,959
Total assets$36.54M$46.13M$58.86M$68.49M$79.23M$87.15M$92.97M$98.13M
Current liabilities$5.50M$7.88M$6.53M$8.02M$6.04M$4.56M$1.90M$2.75M
Total liabilities$5.53M$7.96M$6.66M$8.02M$6.06M$4.61M$1.98M$2.86M
Shareholders' equity$31.01M$38.17M$52.20M$60.47M$73.17M$82.54M$90.98M$95.27M
Shares outstanding91.88M91.88M91.88M91.88M91.88M89.70M89.70M89.70M
Cash flow statement
Operating cash flow-$6.58M-$7.02M-$11.43M-$8.94M-$6.58M-$5.84M-$5.03M-$4.91M
Capital expenditure$0$18,488$37,258$0$0$0$33,948$0
Free cash flow-$6.58M-$7.04M-$11.47M-$8.94M-$6.58M-$5.84M-$5.06M-$4.91M
Investing cash flow-$2.00M-$4.52M-$37,258-$2.00M$0$0-$33,948$0
Financing cash flow$0$0$0$0$0$0-$15,268$14.54M
Depreciation & amortization$7,469$6,647$4,687$4,065$4,066$4,065$4,055$2,934
Stock-based compensation$456,913$528,102$409,220$325,168$323,081$389,114$293,717$231,821

Free plan shows the latest 8 periods; Pro shows all 27 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.